Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Dunleavy Website

Kieron M. Dunleavy, M.D.

Selected Publications

1)  Dunleavy K, Pittaluga S, Shovlin M, Steinberg SM, Cole D, Grant C, Widemann B, Staudt LM, Jaffe ES, Little RF, Wilson WH.
Low-intensity therapy in adults with Burkitt"s lymphoma.
N. Engl. J. Med. 369: 1915-25, 2013.
2)  Dunleavy K, Pittaluga S, Maeda LS, Advani R, Chen CC, Hessler J, Steinberg SM, Grant C, Wright G, Varma G, Staudt LM, Jaffe ES, Wilson WH.
Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma.
N. Engl. J. Med. 368: 1408-16, 2013.
3)  Dunleavy K, Little RF, Pittaluga S, Grant N, Wayne AS, Carrasquillo JA, Steinberg SM, Yarchoan R, Jaffe ES, Wilson WH.
The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma.
Blood. 115: 3017-24, 2010.
4)  Dunleavy K, Pittaluga S, Czuczman MS, Dave SS, Wright G, Grant N, Shovlin M, Jaffe ES, Janik JE, Staudt LM, Wilson WH.
Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma.
Blood. 113: 6069-76, 2009.
5)  Dunleavy K, Hakim F, Kim HK, Janik JE, Grant N, Nakayama T, White T, Wright G, Kwak L, Gress R, Tosato G, Wilson WH.
B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis.
Blood. 106: 795-802, 2005.
6)  Roschewski M, Dunleavy K, Wilson WH.
Moving Beyond R-CHOP for Diffuse Large B-cell Lymphoma.
Leuk. Lymphoma. [Epub ahead of print], 2014.
7)  Klion AD, Mejia R, Cowen EW, Dowdell KC, Dunleavy K, Fahle GA, Holland-Thomas N, Maric I, Pittaluga S, Raffeld M, Santos C, Stetler-Stevenson M, Krogmann T, Shatzer AN, Turk SP, Yin Y, Xi L, Prussin C, Cohen JI.
Chronic active Epstein-Barr virus infection: a novel cause of lymphocytic variant hypereosinophilic syndrome.
Blood. 121: 2364-6, 2013.
8)  Dunleavy K, Wilson WH.
Implications of the shifting pathobiology of AIDS-related lymphoma.
J. Natl. Cancer Inst. 105: 1170-1, 2013.
9)  Lai C, Grant C, Dunleavy K.
Interpreting MYC and BCL2 in diffuse large B-cell lymphoma.
Leuk. Lymphoma. 54: 2091-2, 2013.
10)  Lai C, Dunleavy K.
NK/T-cell lymphomas in children.
Best Pract Res Clin Haematol. 26: 33-41, 2013.
11)  Dunleavy K, Bollard CM.
Scouting out the neighborhood in AIDS-related lymphoma.
Blood. 122: 306-7, 2013.
12)  Davidson-Moncada JK, Pittaluga S, Roth M, Dunleavy K, Duffy A, Pavletic S.
Second cancers early post allogeneic transplant: the case of "unrestrained" malignancy?.
Bone Marrow Transplant. 48: 872-4, 2013.
13)  Lai C, Dunleavy K.
Tackling Burkitt lymphoma in older patients: novel strategies and the promise of targeted agents.
Leuk. Lymphoma. 54: 443-4, 2013.
14)  Wilson WH, Grant C, Dunleavy K.
Therapy in primary mediastinal B-cell lymphoma.
N. Engl. J. Med. 369: 283-4, 2013.
15)  Barta SK, Xue X, Wang D, Tamari R, Lee JY, Mounier N, Kaplan LD, Ribera JM, Spina M, Tirelli U, Weiss R, Galicier L, Boue F, Wilson WH, Wyen C, Oriol A, Navarro JT, Dunleavy K, Little RF, Ratner L, Garcia O, Morgades M, Remick SC, Noy A, Sparano JA.
Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients.
Blood. 122: 3251-62, 2013.
16)  Little RF, Dunleavy K.
Update on the treatment of HIV-associated hematologic malignancies.
Hematology Am Soc Hematol Educ Program. 2013: 382-8, 2013.
17)  Dunleavy K, Grant C, Wilson WH.
Using biologic predictive factors to direct therapy of diffuse large B-cell lymphoma.
Ther Adv Hematol. 4: 43-57, 2013.
Click Here to View Collapsed Bibliography.

This page was last updated on 7/11/2014.